2-[2-[4-(diethylamino)phenyl]vinyl]-1,3,3-trimethyl-3H-indolium acetate

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Justification for type of information:

Data is from experimental study report.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2018

Report date:

2018

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Principles of method if other than guideline:

This study was designed to determine the dermal LD50 of the test item (up to 2000 mg/kg) or to establish a non-lethal dose level of 2000 milligram of test item per kilogram of body weight.

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

2-[[(4-methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium acetate

EC Number:

261-448-2

EC Name:

2-[[(4-methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium acetate

Cas Number:

58798-47-3

Molecular formula:

C20H24N3O.C2H3O2

IUPAC Name:

2-[[(4-Methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium acetate

Test material form:

liquid

Details on test material:

- Name of test material : 2-[[(4-methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium acetate
- IUPAC name: 2-[[(4-Methoxyphenyl)methylhydrazono]methyl]-1,3,3-trimethyl-3H-indolium acetate
- Molecular formula : C20H24N3O.C2H3O2
- Molecular weight : 381.473 g/mol
- Smiles notation : [N+]=1(c2ccccc2C(C)(C)C1\C=N\NCc1ccc(cc1)OC)C.C(C)(=O)[O-]
- InChl : 1S/C20H23N3O.C2H4O2/c1-20(2)17-7-5-6-8-18(17)23(3)19(20)14-22-21-13-15-9-11-16(24-4)12-10-15;1-2(3)4/h5-12,14H,13H2,1-4H3;1H3,(H,3,4)
- Substance type: Organic
- Physical state: Yellow Liquid

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: National Institute of Biosciences, Pune.
- Age at study initiation: Young adult male and female rats aged between 8 – 12 weeks were used.
- Weight at study initiation: The weight range of approximately 223.8 to 246.1 grams at initiation of dosing.
Body weights at the start : Female Mean: 231.32 g (= 100 %); Minimum : 223.8 g (- 3.25 %); Maximum : 246.1 g (+ 6.39 %)
- Identification: Each rat was individually identified by the cage number.
- Housing: The rats were individually housed in polycarbonate cages with paddy husk as bedding.
- Diet (e.g. ad libitum): Rodent feed supplied by the Nutrivet Life Sciences, Pune, was provided ad libitum from individual feeders.
- Water (e.g. ad libitum): Water was provided ad libitum from individual bottles attached to the cages. All water was from a local source and passed through the reverse osmosis membrane before use.
- Acclimation period: 5 days.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.0 to 22.4 degree centigrade.
- Humidity (%): 53.4 % to 58.8%.
- Air changes (per hr): Ten to fifteen air changes per hour.
- Photoperiod (hrs dark / hrs light): An artificial light and dark cycle of 12 hours each was provided to the room.

IN-LIFE DATES: 17-04-2018 to 17-07-2018

Administration / exposure

Type of coverage:

occlusive

Vehicle:

water

Remarks:

(Distilled water)

Details on dermal exposure:

TEST SITE
- Area of exposure: Trunk (dorsal surface and sides from scapular to pelvic area)
- % coverage: Approximately 10% of the body surface area.
- Type of wrap if used: Porous gauze dressing and non-irritating tape.

REMOVAL OF TEST SUBSTANCE
- Washing (if done): Distilled water was used to remove residual test item.

TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- For solids, paste formed: Yes

Duration of exposure:

24 hours

Doses:

A single dose of 2000 mg of the test item per kilogram of body weight was administered to ten rats (five males and five females).

No. of animals per sex per dose:

10 (5/sex).

Control animals:

not specified

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Twice daily
- Necropsy of survivors performed: Yes
- Other examinations performed: Clinical Observations and General Appearance: Animals were observed for clinical signs, mortality, until sacrifice.
Onset, duration and severity of any sign were recorded. The clinical signs and mortality observations were conducted at 10, 30, 60 minutes, 2, 4 and 6 hours on the day of dosing and once daily thereafter for 14 day. Daily observation was done as far as possible at the same time.
The observations were included general clinical signs, observations of eyes, mucous membranes, respiratory, circulatory system and behavior pattern.

Evaluation of Dermal Reaction: Dermal reaction was observed daily for study period of 14 days.

Body weights: Individual animal body weights were recorded pre-test (prior to administration of the test item), day 7 and at termination on day 14.

Gross Pathology: Necropsy was performed on animals surviving at the end of the study. Macroscopic examination of all the orifices, cavities and tissues were made and the findings were recorded. All animals surviving the study period were sacrificed by the carbon dioxide asphyxiation technique (day 15).

Histopathology: No gross abnormalities were observed in animals sacrificed terminally hence, no histopathology was performed.

Statistics:

not specified

Results and discussion

Preliminary study:

not specified

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: no reactions observed

Mortality:

Dose Range Finding Study:
Sex : Female Group I - Animal treated at the dose level of 200 mg/kg body weight: All animals survived through the study period of 14 days.
Sex : Female Group I - Animal treated at the dose level of 1000 mg/kg body weight: All animals survived through the study period of 14 days.
Sex : Female Group I - Animal treated at the dose level of 2000 mg/kg body weight: All animals survived through the study period of 14 days.

Main Study:
Sex : Female Group II - Animal treated at the dose level of 2000 mg/kg body weight: All animals survived through the study period of 14 days.

Clinical signs:

Dose Range Finding Study:
Sex : Female Group I: Animal treated at the dose level of 200 mg/kg body weight did not result in any signs of toxicity during the study period of 14 days.
Sex : Female Group I: Animal treated at the dose level of 1000 mg/kg body weight did not result in any signs of toxicity during the study period of 14 days.
Sex : Female Group I: Animal treated at the dose level of 2000 mg/kg body weight did not result in any signs of toxicity during the study period of 14 days.

Main Study:
Sex : Female Group II: Animal treated at the dose level of 2000 mg/kg body weight did not result in any signs of toxicity during the study period of 14 days.

Body weight:

Dose Range Finding Study:
Sex : Female Group I:(200 mg/kg) - Percent body weight gain after 7 days and 14 days was found to be 5.63% and 10.99% respectively.
Sex : Female Group I (1000 mg/kg) - Percent body weight gain after 7 days and 14 days was found to be 6.70% and 10.63% respectively.
Sex : Female Group I (2000 mg/kg) - Percent body weight gain after 7 days and 14 days was found to be 6.85% and 10.66% respectively.


Main Study:
Sex : Female Group II (2000 mg/kg) : Percent body weight gain after 7 days and 14 days was found to be 5.29% and 8.66% respectively.

Gross pathology:

Gross pathological examination did not reveal any abnormalities in animals from 200mg/kg, 1000 mg/kg and 2000 mg/kg dose group.

Other findings:

- Other observations: Evaluation of Dermal Reaction
Sex : Male Group I - Animal treated at the dose level of 2000 mg/kg body weight did not result in any skin reaction during the study period of 14 days.
Sex : Female Group I - Animal treated at the dose level of 2000 mg/kg body weight did not result in any skin reaction during the study period of 14 days.

Any other information on results incl. tables

Table No. I

Summary of Clinical Signs of Toxicity and Mortality

Test System : Sprague Dawley Rat

Sex : Female

Dose Range Finding Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To	Mortality
I	200	No clinical signs observed	1	1	Day 0- Day 14	0/1

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To	Mortality
I	1000	No clinical signs observed	1	2	Day 0- Day 14	0/1

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To	Mortality
I	2000	No clinical signs observed	1	3	Day 0- Day 14	0/1

Main Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To	Mortality
II	2000	No clinical signs observed	2	4, 5	Day 0- Day 14	0/2

 

 

 

Table No. II

Summary of Evaluation of Dermal Reaction

Test System : Sprague Dawley Rat

Sex : Female

Dose Range Finding Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	200	No dermal reaction observed	1	1	Day 0- Day 14

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	1000	No dermal reaction observed	1	2	Day 0- Day 14

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	2000	No dermal reaction observed	1	3	Day 0- Day 14

 

Main Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
II	2000	No dermal reaction observed	2	4, 5	Day 0- Day 14

Dose Range Finding Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	200	No dermal reaction observed	1	1	Day 0- Day 14

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	1000	No dermal reaction observed	1	2	Day 0- Day 14

 

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
I	2000	No dermal reaction observed	1	3	Day 0- Day 14

 

Main Study:

Group	Dose mg/kg	Observed signs	Total no of animals	Animal no.	Period of signs in days From-To
II	2000	No dermal reaction observed	2	4, 5	Day 0- Day 14

 

 

 

Table No.III

Mean Body Weight and Percent Body Weight Gain (g)

Test System : Sprague Dawley Rat

Sex :Female

Group No.	Dose (mg/kg body weight)		Body weight Day 0	Body weight Day 7	% body weight gain day 0-7	Body weight Day 14	% body weight gain day 7- 14	% body weight gain day 0- 14
I	200	Mean	223.8	236.4	5.63	248.4	5.08	10.99
		± SD	-	-	-	-	-	-

 

Group No.	Dose (mg/kg body weight)		Body weight Day 0	Body weight Day 7	% body weight gain day 0-7	Body weight Day 14	% body weight gain day 7- 14	% body weight gain day 0- 14
I	1000	Mean	228.5	243.8	6.70	252.8	3.69	10.63
		± SD	-	-	-	-	-	-

 

Group No.	Dose (mg/kg body weight)		Body weight Day 0	Body weight Day 7	% body weight gain day 0-7	Body weight Day 14	% body weight gain day 7- 14	% body weight gain day 0- 14
I	2000	Mean	230.7	246.5	6.85	255.3	3.57	10.66
		± SD	-	-	-	-	-	-

 

Main Study:

Group No.	Dose (mg/kg body weight)		Body weight Day 0	Body weight Day 7	% body weight gain day 0-7	Body weight Day 14	% body weight gain day 7- 14	% body weight gain day 0- 14
II	2000	Mean	236.80	249.20	5.29	257.05	3.18	8.66
		± SD	13.15	9.19	1.97	5.30	1.68	3.80

Table No.IV 

Summary of Gross Pathological Findings

Test System : Sprague Dawley Rat

Sex : Female     

Dose Finding Study:

Group No.	Dose mg/kg	Animal Numbers	Animal Fate	Gross Pathological Findings
I	200	1	TS	No abnormality detected

 

Group No.	Dose mg/kg	Animal Numbers	Animal Fate	Gross Pathological Findings
I	1000	2	TS	No abnormality detected

 

Group No.	Dose mg/kg	Animal Numbers	Animal Fate	Gross Pathological Findings
I	2000	3	TS	No abnormality detected

 

                    Main Study:

Group No.	Dose mg/kg	Animal Numbers	Animal Fate	Gross Pathological Findings
II	2000	4, 5	TS	No abnormality detected

 

                     TS = Terminal Sacrifice

               

Applicant's summary and conclusion

Interpretation of results:

other: Not classified

Conclusions:

It was concluded that the acute dermal median lethal dose (LD50) of the given test chemical, when administered to female Sprague Dawley rats was considered to be >2000 mg/kg body weight. Thus, according to CLP criteria for acute toxicity rating for the chemicals, it infers that the given test chemical does not classify as an acute dermal toxicant. CLP Classification: “Not classified”.

Executive summary:

A study was designed and conducted to determine the acute dermal toxicity profile of the given test chemical as per OECD Guideline 402 (Acute Dermal Toxicity) in Sprague Dawley rats.

In the dose range finding study a single dose of 200 mg/kg body weight of the test item was administered to 1 female animal. No death or clinical signs of toxicity was observed during first 48 hours, hence, additional 1 female animal was administered with the dose of 1000 mg/kg body weight. Administration of 1000 mg/kg body weight did not reveal any clinical signs of toxicity or death during first 48 hours, hence, additional 1 female animal was administered at the dose of 2000 mg/kg body weight. Administration of 2000 mg/kg body weight did not reveal any clinical signs of toxicity or death during first 48 hours. As the dose range finding study revealed no mortality or clinical signs at the maximum dose of 2000 mg/kg, the main study was initiated with two additional animals. The animals were administered with a dose of 2000 mg/kg body weight in sequential manner at 48 hours intervals.Animals from dose range finding study treated at the dose levels of 200 mg/kg, 1000 mg/kg and 2000 mg/kg and animals from main study treated at the dose level of 2000 mg/kg exhibited normal body weight gain and revealed no clinical signs of toxicity or mortality during the study period of 14 days. Gross pathological examination did not reveal any abnormalities attributable to the treatment.It was concluded that the acute dermal median lethal dose (LD50) of the given test chemical, when administered to female Sprague Dawley rats was considered to be >2000 mg/kg body weight. Thus, according to CLP criteria for acute toxicity rating for the chemicals, it infers that the given test chemical does not classify as an acute dermal toxicant. CLP Classification: “Not classified”.